Lymphocytosis Management

Evaluation and Diagnosis

For moderate lymphocytosis (absolute lymphocyte count 5-10 × 10^9/L), evaluate for viral causes and consider flow cytometry if persistent, and if a clonal B-cell population is detected, evaluate for CLL/SLL, as recommended by the National Comprehensive Cancer Network 1
Essential laboratory tests for monitoring CLL include complete blood count with differential, serum chemistry panel, and immunophenotyping, to assess disease status and guide treatment decisions, as recommended by the American Society of Hematology 2
Immunophenotyping of peripheral blood should be performed to determine the CLL immunophenotype: CD5+, CD19+, CD20+ (low), CD23+, sIg low, CD79b low, FMC7–, as recommended by the American Society of Hematology 3
Cytogenetic Analysis (FISH) is important for detection of prognostically important abnormalities, including del(17p)/TP53 mutation, del(11q), del(13q), and Trisomy 12, as recommended by the American Society of Hematology 2
IgVH Mutational Status is a prognostic marker that may guide treatment decisions, as recommended by the American Society of Hematology 2
The Binet Staging System and Rai Staging System are used to stage CLL, with specific criteria for each stage, as shown in the table below 4, 5

Stage	Binet Staging System	Rai Staging System
A	Hb ≥10 g/dL, platelets ≥100 × 10^9/L, <3 involved lymphoid sites	Lymphocytosis only
B	Hb ≥10 g/dL, platelets ≥100 × 10^9/L, ≥3 involved lymphoid sites	Lymphocytosis with lymphadenopathy and/or hepatosplenomegaly
C	Hb <10 g/dL and/or platelets <100 × 10^9/L	Lymphocytosis with anemia and/or thrombocytopenia

For early-stage disease without symptoms, a "watch and wait" approach is recommended by the National Comprehensive Cancer Network 1
Treatment is indicated only with progressive disease or symptoms, according to the National Comprehensive Cancer Network 1
Treatment is indicated if patients meet any of the following criteria: progressive marrow failure, massive or symptomatic splenomegaly, massive nodes or progressive/symptomatic lymphadenopathy, progressive lymphocytosis, autoimmune anemia/thrombocytopenia poorly responsive to corticosteroids, or constitutional symptoms, as recommended by the guidelines 2
For fit elderly patients without del(17p)/TP53 mutation, treatment options include bendamustine + rituximab (BR) and R-CVP (rituximab, cyclophosphamide, vincristine, prednisone), as recommended by the guidelines 6
For patients with del(17p)/TP53 mutation, ibrutinib is the preferred first-line therapy, as recommended by the guidelines 6, 7
Allogeneic hematopoietic stem cell transplantation may be considered for patients with del(17p), as recommended by the National Comprehensive Cancer Network and the European Society for Medical Oncology 2, 4

Regular monitoring with clinical examination and blood counts every 3-12 months for asymptomatic MBL/CLL is recommended by the European Society for Medical Oncology 8
More frequent monitoring should be performed for patients on treatment, based on therapy and toxicity profile, as recommended by the European Society for Medical Oncology 8
Pneumococcal and influenza vaccination should be considered for all patients, as recommended by the European Society for Medical Oncology 8
Implement a watch and wait strategy with monitoring every 3 months for patients with stable disease, and monitor for disease progression indicators, as recommended by the American Society of Hematology 3
Regular monitoring with clinical examination and blood counts is essential for patients with CLL to monitor disease progression, treatment-related toxicities, and secondary malignancies, as recommended by the American Society of Clinical Oncology and the European Society for Medical Oncology 8, 9, 2
Patients receiving immune checkpoint inhibitors should have lymphocyte counts monitored according to specific protocols, as recommended by the Journal of Clinical Oncology guidelines 10
Patients with lymphocytosis related to immune checkpoint inhibitor therapy may require different management approaches based on the grade of lymphocytosis, as recommended by the Journal of Clinical Oncology guidelines 10

Autoimmune hemolytic anemia occurs in 10-15% of CLL patients, and direct antiglobulin test and platelet counts should be monitored, as recommended by the American Society of Hematology 3, 11
Disease transformation, including Richter's syndrome, should be monitored, with signs including rapid lymph node growth and elevated LDH, as recommended by the American Society of Hematology 11
Overlooking infectious complications due to immunosuppression from both disease and treatment is a concern, as recommended by the American Society of Hematology 2
HIV Testing is important before initiating immunosuppressive therapy, as recommended by the American Society of Hematology 2
Hepatitis B and C Screening is critical before starting immunosuppressive therapy, with HBV carriers requiring prophylactic antiviral therapy, as recommended by the American Society of Hematology 2

Failing to distinguish monoclonal B lymphocytosis from CLL, overlooking medication effects as causes of lymphopenia, and treating lymphocytosis based solely on absolute count rather than clinical symptoms, as warned by the American College of Physicians 4
Missing transformation to aggressive lymphoma in patients with known indolent lymphoproliferative disorders and overlooking protein-losing enteropathy as a cause of lymphopenia, as advised by the National Comprehensive Cancer Network 4, 12
Overlooking the possibility of transformation to more aggressive lymphoma (Richter's transformation), as stated by the American Society of Clinical Oncology 4
Treating based on absolute lymphocyte count alone, rather than clinical symptoms or disease progression, is not recommended, and diagnosing CLL without immunophenotyping is not sufficient, as stated in the guidelines 13